STATEMENTS OF CASH FLOWS - USD ($)	6 Months Ended
	Aug. 31, 2023	Aug. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (539,509)	$ (447,655)
Adjustments to reconcile net loss to net cash used by operating activities:
FDA clinical trial expenses paid directly by S.R. Burzynski M.D., Ph.D.	363,226	306,277
Changes in operating assets and liabilities
Prepaids	600	879
Accounts payable	(12,570)	1,935
Accrued liabilities	3,182	9,914
NET CASH USED BY OPERATING ACTIVITIES	(185,071)	(128,650)
CASH FLOWS FROM FINANCING ACTIVITIES
Contribution of capital	185,534	126,534
NET CASH PROVIDED BY FINANCING ACTIVITIES	185,534	126,534
NET INCREASE (DECREASE) IN CASH	463	(2,116)
CASH AT BEGINNING OF PERIOD	934	3,382
CASH AT END OF PERIOD	$ 1,397	$ 1,266